These are preliminary reports that have not been peer-reviewed. They should not be regarded as conclusive, guide clinical practice/health-related behavior, or be reported in news media as established information. For more information, please see our FAQs.
2 files

Strategy for Lead Identification for Understudied Kinases

submitted on 10.03.2021, 20:16 and posted on 11.03.2021, 11:00 by David Drewry, Joel K. Annor-Gyamfi, Carrow Wells, Julie E. Pickett, Alison Axtman

In our manuscript we outline an approach in which we convert a promiscuous pyrimidine scaffold into narrowly selective, cell-active chemical leads for several understudied kinases, including DRAK1, BMP2K, and MARK4. These chemical tools will allow illumination of the function(s) of these poorly characterized kinases for the first time. Several of the understudied kinases that we inhibit with our pyrimidine-based compounds are also implicated in neurodegenerative disease, pushing the utility of kinase inhibitors outside of the oncology space and offering opportunities for the validation of therapeutic hypotheses attributed to these kinases.


NC Biotechnology Center Institutional Support Grant 2018-IDG-1030

NIH 1U24DK116204

NIH U54AG065187

Department of Defense AL190107

ALS Association wa1127

Canada Foundation for Innovation

Eshelman Institute for Innovation

Genome Canada

Innovative Medicines Initiative

Ontario Ministry of Economic Development and Innovation

São Paulo Research Foundation- FAPESP

Wellcome Trust


Email Address of Submitting Author


University of North Carolina at Chapel Hill


United States

ORCID For Submitting Author


Declaration of Conflict of Interest

No conflict of interest